epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-118, Phase II. In start-up

Treatment-resistant major depressive disorder

FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.

QTLs at a glance

Data to September 30th 2026. Each measure links to its chart below.

Missing primary endpoint data

Too early

Too early Fewer than 50 patients

Lost to follow-up or withdrew consent

Too early

Too early Fewer than 50 patients

Stopped study treatment early

Too early

Too early Fewer than 50 patients

Ineligible patients randomised

Too early

Too early Fewer than 50 patients

Will the result hold?

Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.

RankQTLLikelihoodImpactWhy it is likely hereWatched at sites byWarningLimitCritical
1Missing primary endpoint dataEvidence grade A23
  • Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
  • Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
17.4%25.9%41.7%
2Lost to follow-up or withdrew consentEvidence grade A23
  • Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
  • Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
4.5%6%24.3%
3Stopped study treatment earlyEvidence grade B32
  • Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
  • Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
12.5%15%22%
4Ineligible patients randomisedEvidence grade B32
  • Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? Three or more
  • Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? Three or more; Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? Three or more
  • Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? Three or more
4%5%14.5%

Missing primary endpoint data

Too early to judge% of patients; benchmark median 7.9%

The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it

Lost to follow-up or withdrew consent

Too early to judge% of patients; benchmark median 3.7%

epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status

Stopped study treatment early

Too early to judge% of patients; benchmark median 10.7%

epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power

Ineligible patients randomised

Too early to judge% of patients; benchmark median 3.2%

epiClinical assumption: above the 3.2% median; eligibility errors were reported in 39% of 82 trials

Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).

Breaches and decisions

No QTL in EPI-118 has passed its early-warning line, so nothing needs evaluating.

Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.